Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiomax in HIT/HITTS Off-Pump CABG (CHOOSE-OFF)
NCT00073580Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Oct 2003
- Primary completion
- Sep 2005
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bivalirudin in heparin-induced thrombocytopenia (HIT), sponsored by The Medicines Company. Primary endpoint: Procedural Success at 7 days. Started Oct 2003; status: completed.
02
Drugs
bivalirudin
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT00073580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073580.